Mike joined Catamaran as Senior Vice President, Corporate Strategy and New Product Planning in February 2022. He has extensive experience leading product planning and portfolio strategy in the cell therapy and immuno-oncology areas. Prior to Catamaran, Mike was Vice President, Medicine Commercialization Leader for Cell and Gene Therapies at GlaxoSmithKline (GSK). In this role he was responsible for planning the global launch of letetresgene autoleucel (NY-ESO-1 TCR-T cell therapy), operational design and implementation of GSK’s cell therapy capabilities, and for cell therapy portfolio strategy. He also made major contributions to GSK’s reentry into oncology by playing a leading role in the company’s $5B acquisition of Tesaro in 2019. Prior to this, he held roles of increasing responsibility at GSK in new product planning and business development across a range of disease areas. Mike began his career as a strategy consultant at LEK Consulting. Mike holds a PhD in Biomedical Engineering from the University of Pennsylvania and a BSE in Bioengineering from Tulane University.